#SMYD3 methylates #cMYC at K158/K163 residues to sustain stemness, self-renewal & #metastasis in #ColorectalCancer stem cells; its inhibition disrupts #clonogenicity and tumorigenicity, positioning the SMYD3/c-MYC axis as a therapeutic target in #CRC.

#STTT: doi.org/10.1038/s413...

#SMYD3 methylates #cMyc to sustain #ColorectalCancer stem cell self‑renewal and #metastasis; inhibition of SMYD3 reduces #clonogenicity, #tumorigenicity, and dissemination, highlighting the SMYD3/c‑MYC axis as a therapeutic target for CRC.

#CoverPage #STTT: doi.org/10.1038/s413...